﻿ Iressa (gefitinib): Q&A on FDA Approval - Lungs: Pulmonary and
Respiratory Health and Medical Information Produced by Doctors
Questions and Answers on Iressa (gefitinib)  On June 17, 2005
the The Food and Drug Administration (FDA) has approved new
labeling for gefitinib (Iressa) that limits use to patients with
cancer who in the opinion of their treating physician, are
currently benefiting, or have previously benefited, from Iressa
treatment. In addition, AstraZeneca will distribute the drug
under the Iressa Access Program. For more, please read the
"Questions and Answers on Iressa's (gefitinib) New Labeling"
article.  Iressa (gefitinib) is a groundbreaking new type of
anti-cancer drug for people with the most common type of lung
cancer. It is different from all prior chemotherapy. That is,
Iressa works by uniquely blocking cellular enzymes that
stimulate cell growth. So, in the future, look for the emergence
of other (hopefully more effective) anti-cancer drugs that work
at specific cellular or molecular